Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp POLE R34L |
Therapy | Pembrolizumab |
Indication/Tumor Type | small intestine adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp POLE R34L | small intestine adenocarcinoma | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, Keytruda (pembrolizumab) treatment resulted in a reduction of primary tumor and metastatic lesions and an ongoing progression-free survival at 31 months in a patient with microsatellite stable (MSS) ileum adenocarcinoma that had high CD274 (PD-L1) expression (TPS = 75%) and harbored POLE R34L, but had low tumor mutational burden (PMID: 34875656). | 34875656 |
PubMed Id | Reference Title | Details |
---|---|---|
(34875656) | PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation. | Full reference... |